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Vessels Encapsulating Tumor Clusters 
(VETC) Is a Powerful Predictor of 
Aggressive Hepatocellular Carcinoma
Salvatore Lorenzo Renne ,1* Ha Young Woo,2* Sarah Allegra,1* Noemi Rudini,1 Hirohisa Yano,3 Matteo Donadon,4,5  
Luca Viganò,4,5 Jun Akiba,6 Hye Sun Lee,7 Hyungjin Rhee,8 Young Nyun Park,2 Massimo Roncalli,1,5 and Luca Di Tommaso1,5
We investigated the clinical significance of a vascular growth pattern of hepatocellular carcinoma (HCC), the 
vessels that encapsulate tumor clusters (VETC), previously linked to HCC metastatic dissemination. VETC was 
assessed in a large multi-institutional cohort of 541 resected HCCs from Italy, Korea and Japan, and matched 
against a full spectrum of clinical and pathological variables. The VETC phenotype (defined as  ≥  55% tumor area 
by CD34 immunostaining) was easily reproducible and reliably detectable in whole sections and small-sized tissues 
of tissue microarray. VETC HCCs represented 18.9% of the whole series, the lowest proportion occurring in the 
cohort with smallest tumors (8.7%, Japanese series). VETC was significantly associated with several clinical and 
pathological features such as high alfa-fetoprotein (AFP) level, tumor size greater than 5 cm, poor differentiation, 
macrotrabecular pattern, less compact pattern, less inf lammatory infiltrates, and frequent microvascular invasion. 
VETC was associated with early recurrence (hazard ratio [HR]: 1.52 [1.06-2.19], P  =  0.023), disease-free survival 
(HR: 1.66 [1.21-2.27], P  =  0.002), and overall survival (HR: 2.26 [1.37-3.72], P  =  0.001) at multivariable analysis. 
VETC affected the survival in HCC patients stratified for etiology (hepatitis C virus/hepatitis B virus), vascular 
invasion, and specific molecular phenotypes (β-catenin/GS+). This distinct vascular pattern was enriched in the re-
cently reported macrotrabecular massive HCC subtype, which was seen in 7.8% (42 of 541) of patients and associ-
ated with high AFP levels and poor differentiation. Conclusion: The VETC pattern was found to be easily detectable 
in a consistent fraction of HCC and a powerful pathological finding affecting survival. This study suggests that the 
heterogeneous pattern of angiogenesis is involved in HCC behavior. (Hepatology 2020;71:183-195).
The development of hepatocellular carcinoma (HCC) is a multistep process from precan-cerous lesions (dysplastic nodule) to early and 
advanced HCC.(1) This has been widely investigated, 
as most research has been focused on morphological, 
phenotypical, and molecular features of the neoplas-
tic cells (i.e., hepatocytes), whereas less attention has 
been dedicated to the dynamic changes of microen-
vironmental nontumoral supporting cells. Among this 
heterogeneous population, endothelial cells in HCC 
are of particular interest because they are strikingly 
involved in the tumor growth and represent a potential 
therapeutic target (transarterial chemoembolization, 
drugs). Intratumoral endothelial cells progressively 
lose sinusoidal markers, including stabilin-1, stabilin-2, 
LYVE-1 (lymphatic vessel endothelial hyaluronan 
receptor 1), CD32 (cluster of differentiation 32/34), 
and ICAM (intercellular adhesion molecule 1)(2); at 
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the same time, they gain markers of continuous, non-
fenestrated endothelial cells (i.e., capillary), such as 
CD34.(3,4) Accordingly, the process of pathological 
angiogenesis in HCC is mostly known as capillariza-
tion. We have recently shown that dysplastic nodule 
and early HCC are characterized by a focal, if any, 
sinusoidal capillarization/incomplete angiogenesis.(5) 
In contrast, diffuse capillarization/complete angiogen-
esis was seen in 33% of small and progressed HCC 
(pHCC), and in up to 90% of pHCC arisen in the 
so-called nodule in nodule HCC.(5,6) As in many other 
solid tumors, once angiogenesis is completed, HCC is 
more prone to progress and to metastasize. Moreover, 
a shift from a “dormant” angiogenesis that supports 
tumor growth, but not metastases, to an “active” more 
aggressive, pro-metastatic angiogenesis has been pos-
tulated in many organs.(7,8) Interestingly, a signature 
of five genes (angiopoietin-2 [ANGPT2], delta-like 
ligand 4 [DLL4], neuropilin/tolloid-like 2 [NETO2], 
endothelial cell-specific molecule-1 [ESM1], and 
nuclear receptor subfamily 4, group A, member 1 
[NR4A1]), all related to angiogenesis, characterized a 
subset of highly aggressive and fast-growing HCC at 
onset.(9) It is therefore likely that vascular pattern het-
erogeneity can also play a role in tumor progression.(10) 
Interestingly, Fang et al. reported a distinct pattern of 
HCC vascularization that predicted rapid tumor dis-
semination and high recurrence rates.(11) This pattern 
is characterized by the presence of CD34+ vessels 
completely encapsulating tumor clusters (VETC).(11) 
Although conducted in a limited HCC population 
(hepatitis B virus [HBV]-related and >5 cm), the 
authors elegantly showed VETC clusters delivering 
tumor emboli into larger vessels. Moreover, the same 
authors recently claimed sorafenib therapy to be more 
effective in VETC HCC.(12)
To lend further support to the hypothesis that a 
VETC pattern can primarily affect patient prognosis, 
we collected a large series of surgically resected HCCs 
with various etiologies from different geographic areas 
of high HCC incidence, where VETC was evaluated 
against consolidated and novel prognostic markers.
Materials and Methods
patIeNtS aND SaMpleS
The series included 541 HCCs (541 patients) 
treated by surgical resection in three different 
Institutions (Humanitas Research Hospital [Rozzano, 
Italy], Severance Hospital [Seoul, Korea], and Kurume 
University Hospital [Kurume, Japan]), consecutively 
collected from 2006 to 2012 and with available fol-
low-up of not less than 2 years. Only cases staged R0 
after surgical resection were included in the study. The 
clinical outcomes of the patients were obtained retro-
spectively by reviewing the electronic medical records. 
The endpoints were defined as follows: Overall sur-
vival (OS) was defined by the interval between sur-
gery and death regardless of cause; and disease-free 
survival (DFS) was defined as the time from surgery 
to an initial diagnosis of recurrence regardless of loca-
tion. The mean follow-up duration was 52 months. 
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The study protocol conforms to the ethical guidelines 
of the 1975 Declaration of Helsinki, as reflected in 
a priori approval by the institution’s human research 
committee. This study was approved by the institu-
tional review boards of the three hospitals, and the 
requirement for informed consent was waived.
The following clinical features were systematically 
recorded: age, gender, etiology of chronic liver dis-
ease (HBV, hepatitis C virus [HCV], alcohol intake, 
other), and pre-operative alpha-fetoprotein (AFP) 
serum levels and follow-up. Staging according to the 
Barcelona Clinic of Liver Cancer (BCLC) system was 
also available in most cases.
patHologICal eXaMINatIoN
The following features were analyzed regarding 
the general macroscopic characteristics: tumor size, 
multiplicity, and macrovascular invasion. Regarding 
the general microscopic features, the following were 
analyzed: tumor grade (according to Edmondson-
Steiner); pattern of growth (at least 20% of the tumor 
area: microtrabecular, macrotrabecular, compact, or 
pseudoglandular); microvascular invasion; tumor cap-
sule; inflammatory infiltrate; and cirrhosis of the sur-
rounding liver parenchyma. Moreover, the following 
tumoral cytological findings were recorded: cholesta-
sis, clear, multinucleated and pleomorphic cells, sar-
comatous changes, and hyaline bodies. The tumoral 
subtype (scirrhous, lymphoepithelioma-like, sarcoma-
toid, steatohepatitic, and the recently described mac-
rotrabecular massive [MTM] subtype, the latter in at 
least 50% tumor area(13,14)) and several phenotypic 
markers (glutamine synthetase [GS], β-catenin, p53, 
and CD34) were also recorded.
All available histological slides were reviewed by 
at least 2 expert liver pathologists (L.D.T., H.Y.W., 
Y.N.P., M.R., H.Y., and J.A.), who were blinded to 
the clinical data.
IMMUNoHIStoCHeMIStRy
Tissue microarrays (TMAs; diameter ranging from 
1-2 mm) from the surgical specimens were used to 
investigate the expression of phenotypic markers. Six 
different tumoral cores were obtained from central 
(n° 3) and peripheral areas (n° 3); three additional 
spots were also obtained from the surrounding liver 
parenchyma.
Immunohistochemical stain was performed 
using an automated staining system (Discovery XT; 
Ventana Medical Systems, Oro Valley, AZ) according 
to the manufacturer’s instructions; antibodies, sources, 
clones, and dilutions are detailed in Supporting Table 
S1. The quantification of the phenotypic markers was 
done as follows: positivity was defined as unequivo-
cal immunoreactivity (GS [cytoplasmic], β-catenin 
[nuclear], and p53 [nuclear]) in at least 50% of the 
tumor hepatocytes. Regarding CD34 evaluation, 
unequivocal immunoreactivity of a continuous lining 
around tumor clusters was defined as VETC, and the 
area of VETC was semi-quantitatively evaluated from 
0% to 100% in 5% of the units. This VETC pattern 
was considered alternative to the other common cap-
illary pattern, sustained by the growth of small circular 
vessels. Both patterns are illustrated in Supporting Fig. 
S1. To check the correlation between the VETC of 
whole sectioned slides and that of TMAs, an immu-
nohistochemical stain for CD34 was performed in 
matched whole sections and the TMAs of 96 HCCs.
StatIStICal aNalySIS
Categorical variables were compared using the χ2 
test or Fisher’s exact test. Kaplan-Meier survival curves 
and log-rank statistics were used to evaluate the time 
to early (≤2 years) or late (>2 years) recurrence and OS. 
Multivariable regression analysis was performed using 
the Cox proportional hazards model. After we confirmed 
that VETC is a meaningful prognostic factor as a con-
tinuous variable, we used the K-adaptive partitioning 
algorithm to find the point at which the log-rank statis-
tics are maximized and obtained the optimal cutoff value.
The intraclass correlation coefficient was used to 
compare the VETC (percentage) of surgical speci-
mens and TMAs in 96 cases, and the Fleiss’ kappa 
value was used to compare the agreement of the 4 
reviewers (H.Y.W., Y.N.P., M.R., and L.D.T.) in 
60 cases. Both values were considered to be good 
agreement when it was 0.6 or more.
All statistical analyses were performed using SPSS 
software (version 21.0; IBM Statistics, Armonk, NY) 
and R software (version 3.5.1 for Windows; the R 
foundation for statistical computing, Vienna, Austria). 
All statistical tests were two-tailed; P < 0.05 was con-
sidered statistically significant, and 0.05 ≤ P < 0.1 was 
considered a trend toward significance, to increase the 
sensitivity to detect potential selection bias.





The clinico-pathologic features of the whole series 
are reported in Table 1, and those of Italian, Korean, 
and Japanese cohorts are summarized in Supporting 
Table S2.
Briefly, there was a strong male predominance 
(78.2%). Most of the cases were related to HBV 
(51.8%) or HCV (34.8%) infections, and rarely to 
alcohol intake (5.5%). Most of the Italian and Korean 
cases were BCLC 0/A (85.2%). Most HCCs were 
5 cm or less (82.4%), and the Japanese cohort showed 
the smallest HCCs (0.8%  >  5 cm). Multiple tumors 
accounted for 16.3%. Poorly differentiated HCCs 
(Edmondson grade III-IV) were seen in 46.6%. An 
taBle 1. Clinical, pathological, and phenotypical Features of the Whole HCC Series (n = 541)
Variables n (%)
Clinical Features
Age (>60 years) 290 (53.6)
Gender (male/female) 423 (78.2)/118 (21.8)
Etiology (HBV/HCV/alcohol/undetermined) 280 (51.8)/188 (34.8)/30 (5.5)/43 (7.9)
BCLC (0/A/B/C)* 42 (10.1)/311 (75.1)/38 (9.2)/23 (5.6)
Pre-operative serum AFP >400 ng/mL 95 (17.6)
Pre-operative treatment 20 (3.7)
General Macroscopic
Tumor size >5 cm 95 (17.6)
Multiplicity 88 (16.3)
Macrovascular invasion 31 (5.7)
General Microscopic
Edmondson grade I-II/III-IV 289 (53.4)/252 (46.6)
Microtrabecular/macrotrabecular/pseudoglandular/compact 398 (73.6)/307 (56.7)/195 (36.0)/234 (43.3)
Microvascular invasion 292 (54.0)
Capsule infiltration 297 (54.9)
Inflammatory infiltrates 144 (26.6)
Fibrosis of parenchyma (METAVIR F0-F3/F4) 270 (49.9)/271 (50.1)
Tumoral Cytological Findings
Tumoral cholestasis/clear cells 93 (17.2)/159 (29.4)
Pleomorphic cells/multinucleated cells 156 (28.8)/148 (27.4)
Sarcomatous changes/hyaline bodies 12 (2.2)/113 (20.9)
Tumoral Variants
Scirrhous/lymphoepithelioma-like/sarcomatoid/steatohepatitic/ macrotrabecular-massive 8 (1.5)/6 (1.1)/3 (0.6)/38 (7.0)/42 (7.8)




Double positive 11 (2.0)




Early recurrence (≤2 years) 174 (32.7)
Late recurrence (>2 years) 66 (12.4)
*Available in 414 cases.
†p53+: p53+ and βcatenin/GS-; βcatenin/GS+: p53- and βcatenin/GS+; double positive: p53+ and βcatenin/GS+; and double 
negative: p53- and βcatenin/GS-.
‡Available in 532 cases.
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average of 3.3 architectural patterns or cytological 
features were observed in each case. Microtrabecular, 
macrotrabecular, pseudoglandular, and compact 
patterns were identified in 73.6%, 56.7%, 36.0%, 
and 43.3% of the tumors, respectively. MTM HCC 
was the most common subtype identified (7.8%), 
followed by steatohepatitic (7%), scirrhous (1.5%), 
lymphoepithelioma-like (1.1%), and sarcomatoid 
HCC (0.6%).
HCCs were further classified according to the fol-
lowing molecular phenotypes: p53+ and β-catenin/GS- 
(briefly: p53+) 20.0%; p53- and β-catenin/GS+ (briefly: 
β-catenin/GS+) 22.6%; p53+ and β-catenin/GS+ 
(briefly: double positive) 2.0%; and p53- and 
β-catenin/GS- (briefly: double negative) 55.5%.
Follow-up data were available for 532 patients: 
recurrence and death occurred in 45.1% (240 of 532) 
and 18.0% (96 of 532) of HCC patients, respectively. 
Early (≤2 years) and late (>2 years) recurrence was 
observed in 32.7% (174 of 532) and 12.4% (66 of 
532) of HCC in the whole series.
VetC patteRN IS a RoBUSt 
pReDICtoR oF HCC 
aggReSSIVeNeSS, RelateD to 
VaSCUlaR peRMeatIoN
The degree of VETC positive area ranged from 0% 
to 100% of the tumor surface. The reliability between 
VETC of whole sectioned slides and that of TMA 
was evaluated in 96 matched cases, and it was good 
(intraclass correlation coefficient [95% confidence 
interval (CI): 0.642] 0.489-0.733); then VETC was 
evaluated in a total of 541 HCCs using TMA. At 
least 5% VETC tumor area was seen in 39.0% (222 
of 541) of HCCs, and the median value of VETC 
was 0% (Q1-Q3, 0%-35%). Multivariable regression 
analysis with the collected parameters confirmed that 
VETC, evaluated in 5% unit, was a meaningful prog-
nostic factor. VETC was significantly associated with 
poorer DFS and OS (DFS HR: 1.02 [1.00-1.05]; 
P = 0.019; OS HR: 1.04 [1.01-1.07]; P = 0.020) and 
with a tendency toward early relapse (HR: 1.02 [1.00-
1.05]; P = 0.094) at multivariable analysis.
By using K-adaptive partitioning algorithm, we set 
a value of 55% as the optimal cutoff value of VETC 
phenotype to predict prognosis. By applying the cutoff 
value of VETC 55%, HCCs were further divided into 
VETC-HCC and non-VETC-HCC. The agreement 
of the VETC phenotype among 4 reviewers (H.Y.W., 
L.D.T., M.R., and Y.N.P.) was good (Fleiss’ kappa value 
[95% CI]: 0.887 [0.784-0.991]). The VETC phenotype 
(≥55%) was observed in 18.9% of HCCs (102 of 541) 
and was found in 23.5% of the Italian cohort, 21.5% of 
the Korean cohort, and 8.7% of the Japanese cohort. The 
VETC phenotype was not associated with specific etio-
logic factors. It was significantly higher in HCC patients 
with high AFP serum level (>400 ng/mL, P  <  0.001), 
larger tumor size (>5 cm, P < 0.001), Edmondson grade 
III-IV (P < 0.001), macrotrabecular pattern (P < 0.001), 
MTM subtype (P  =  0.006), microvascular invasion 
(P < 0.001), and less inflammatory infiltrates (P = 0.013). 
A trend toward significance was found for macrovascular 
invasion (P  =  0.059). For molecular subgroups, VETC 
was enriched in β-catenin/GS+ and in the double- 
positive HCC (P  =  0.025 and P  =  0.038, respectively) 
and impoverished in double-negative HCC (P = 0.006) 
phenotypes (Fig. 1A,B and Table 2).
VETC HCC revealed earlier recurrence, poorer 
DFS and OS compared with non-VETC HCC in the 
whole cohorts (n  =  532) (P  <  0.05 for all) (Fig. 1C). 
The significant clinical impact of VETC pheno-
type was confirmed at multivariable analysis for early 
recurrence (HR 1.52 [1.06-2.19]; P  =  0.023), DFS 
(HR 1.66 [1.21-2.27]; P  = 0.002), and OS (HR 2.26 
[1.37-3.72]; P  =  0.001) (Table 3). The VETC phe-
notype affected early recurrence, DFS, and OS even 
when HCC patients were stratified according to etiol-
ogies of HBV (n = 280) and HCV (n = 179) (P < 0.05 
for all) (Supporting Fig. S2A). A predictive value of 
VETC phenotype on early HCC recurrence, DFS, 
and OS was also retained for HCCs of up to 5 cm 
(n = 444; P < 0.05 for all); a trend toward significance 
was present in OS for those greater than 5 cm (n = 88) 
(Supporting Fig. S2B). It was also associated with early 
recurrence, DFS, and OS for HCCs with micro/macro-
vascular invasion (n = 289; P < 0.05 for all), and poorer 
DFS for those without micro/macrovascular invasion 
(n = 243; P = 0.038) (Supporting Fig. S2C). For molec-
ular phenotype, the VETC phenotype remained a sig-
nificant predictive factor of early recurrence and OS in 
β-catenin/GS+ (n = 120) and double negative (n = 297; 
P < 0.05 for all), but not in p53+ (n = 104) phenotypes 
(Supporting Fig. S2D). Among three independent 
cohorts, the VETC phenotype was a significant pre-
dictive factor for early HCC recurrence, DFS, and OS 
in the Italian and Korean cohorts (P < 0.05 for all), but 
not in the Japanese cohorts (Supporting Fig. S3).
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VetC IS eNRICHeD IN tHe MtM 
SUBtype HCC
VETC was significantly enriched in the MTM 
subtype HCC (P = 0.006). The MTM subtype was 
seen in 7.8% (42 of 541) of HCCs (Fig. 2A), and it 
was not associated with specific etiological factors. 
MTM showed a significant correlation with clinical 
and pathological features of aggressiveness such as 
high AFP serum levels (>400 ng/mL, P  <  0.001), 
Edmondson grade III-IV (P  =  0.001), and less 
pseudoglandular pattern (P  =  0.019). Interestingly, 
among molecular phenotypes, MTM was signifi-
cantly higher in p53+ and double-positive pheno-
types (P  <  0.001 and P  =  0.046, respectively) and 
lower in β-catenin/GS+ phenotype (P  =  0.006) 
(Fig. 2B and Table 4). MTM showed no signifi-
cant difference in early recurrence, DFS, and OS 
in whole series in univariable analysis (Table 3 and 
Fig. 2C).
IMpaCt oN pRogNoSIS oF 
FeatUReS otHeR tHaN VetC
Several other clinical and pathological parameters 
showed an impact on early recurrence, DFS, and 
OS at multivariable analysis. Focusing on patho-
logic features, some of them (number and size of 
tumor, macrovascular invasion, and cirrhosis) can 
be detected at imaging and are already part of the 
current staging systems for HCC such as BCLC. 
Other parameters can be detected only under the 
microscope. Among the latter, the sarcomatoid vari-
ant showed a robust association with DFS (HR 
8.72 [1.17-64.76]; P  =  0.034) and OS (HR 24.99 
[3.05-204.63]; P  =  0.003); however, this variant is 
extremely rare (3 of 541, 0.6%). Microvascular inva-
sion (HR 2.19 [1.31-3.66]; P  =  0.003) and hyaline 
bodies (HR 1.80 [1.13-2.87]; P = 0.013) were asso-
ciated with shorter OS, whereas microtrabecular 
pattern was associated with longer OS (HR 0.59 
FIg. 1. (A) Morphologic features of VETC HCC. This HCC shows clusters of tumor cells bordered by a complete rim of CD34-
positive endothelial cells in more than half of the tumor area (i.e., VETC phenotype). (B) Clinical and pathologic features associated 
with VETC HCC (*P < 0.05, **P < 0.001; χ2 test). (C) Impact of VETC phenotype on survival of HCC patients.
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[0.37-0.95]; P = 0.029) (Table 3). Although molec-
ular phenotypes had a significant association with 
several clinical and pathological features (Fig. 3, 
Supporting Tables S3-S4), they did not show sig-
nificant association with early recurrence, DFS, and 
OS in the multivariable model (Table 3).
taBle 2. Clinical and pathological Features associated With VetC HCC (n = 541)
n (%) Non-VETC HCC (n [%]) VETC HCC (n [%]) P Value
Clinical Features
Age >60 years 290 (53.6) 233 of 439 (53.1) 57 of 102 (55.9) 0.660
Male sex 423 (78.2) 345 of 439 (78.6) 78 of 102 (76.5) 0.690
Alcohol 30 (5.5) 24 of 439 (5.5) 6 of 102 (6.8) 1.000
HCV infection 188 (34.8) 155 of 439 (35.3) 33 of 102 (32.4) 0.645
HBV infection 280 (51.8) 223 of 439 (50.8) 57 of 102 (55.9) 0.380
BCLC stage B-C* 61 (14.7) 41 of 323 (12.7) 20 of 91 (22.0) 0.031
AFP serum level >400 ng/mL 95 (17.6) 63 of 439 (14.4) 32 of 102 (31.4) <0.001
Pre-operative treatment 20 (3.7) 16 of 439 (3.6) 4 of 102 (3.9) 0.772
General Macroscopic
Tumor size >5 cm 95 (17.6) 60 of 439 (13.7) 35 of 102 (34.3) <0.001
Multiplicity 88 (16.3) 68 of 439 (15.5) 20 of 102 (19.6) 0.371
Macrovascular invasion 31 (5.7) 21 of 439 (4.8) 10 of 102 (9.8) 0.059
General Microscopic
Edmondson grade III-IV 252 (46.6) 184 of 439 (41.9) 68 of 102 (66.7) <0.001
Microtrabecular pattern 398 (73.6) 318 of 439 (72.4) 80 of 102 (78.4) 0.262
Macrotrabecular pattern 307 (56.7) 227 of 439 (51.7) 80 of 102 (78.4) <0.001
Pseudoglandular pattern 195 (36.0) 156 of 439 (35.5) 39 of 102 (38.2) 0.647
Compact pattern 234 (43.3) 202 of 439 (46.0) 32 of 102 (31.4) 0.008
Microvascular invasion 292 (54.0) 210 of 439 (47.8) 82 of 102 (80.4) <0.001
Capsule infiltration 297 (54.9) 233 of 439 (53.1) 64 of 102 (62.7) 0.079
Inflammatory infiltrates 144 (26.6) 127 of 439 (28.9) 17 of 102 (16.7) 0.013
Cirrhosis 271 (50.1) 216 of 439 (49.2) 55 of 102 (53.9) 0.442
Tumor Cytological Findings
Cholestasis 93 (17.2) 70 of 439 (15.9) 23 of 102 (22.5) 0.144
Clear cells 159 (29.4) 129 of 439 (29.4) 30 of 102 (29.4) 1.000
Pleomorphic cells 156 (28.8) 121 of 439 (27.6) 35 of 102 (34.3) 0.183
Multinucleated cells 148 (27.4) 110 of 439 (25.1) 38 of 102 (37.3) 0.014
Sarcomatous changes 12 (2.2) 10 of 439 (2.3) 2 of 102 (2.0) 1.000
Hyaline bodies 113 (20.9) 92 of 439 (21.0) 21 of 102 (20.6) 1.000
Tumor Variants
Lymphoepithelioma-like 6 (1.1) 6 of 439 (1.4) 0 of 102 (0.0) 0.600
Sarcomatoid 3 (0.6) 3 of 439 (0.7) 0 of 102 (0.0) 1.000
Scirrhous 8 (1.5) 8 of 439 (1.8) 0 of 102 (0.0) 0.363
Steatohepatitic 38 (7.0) 29 of 439 (6.6) 9 of 102 (8.8) 0.518
Macrotrabecular-massive 42 (7.8) 27 of 439 (6.2) 15 of 102 (14.7) 0.006
Molecular Phenotype†
p53+ 108 (20.0) 87 of 439 (19.8) 21 of 102 (20.6) 0.891
βcatenin/GS+ 122 (22.6) 90 of 439 (20.5) 32 of 102 (31.4) 0.025
Double positive 11 (2.0) 6 of 439 (1.4) 5 of 102 (4.9) 0.038
Double negative 300 (55.5) 256 of 439 (58.3) 44 of 102 (43.1) 0.006
*Available in 414 cases.
†p53+: p53+ and βcatenin/GS-; βcatenin/GS+: p53- and βcatenin/GS+; double positive: p53+ and βcatenin/GS+; and double negative: 
p53- and βcatenin/GS-.
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Discussion
This paper aimed to evaluate the robustness of the 
impact on survival of a vascularization pattern of HCC 
named VETC, in a large cohort of patients from differ-
ent geographic areas (Italy, Korea, and Japan). VETC 
HCC accounted for 18.9%, regardless of etiology, a pro-
portion of enough size to capture a consistent and clin-
ically significant fraction of HCC. Our study confirms 
the prognostic impact of VETC on a large multicenter 
cohort. Interestingly Fang et al. reported 39% VETC 
HCC, but in that series the authors did not use the 
more selective 55% cutoff value for VETC; moreover, 
75% of HCCs were greater than 5 cm (versus 17.6% in 
the present study), suggesting that this specific vascular 
pattern could be related to the tumor progression.(11) 
Indeed, in the Japanese cohort of the present series, 
which included the smallest tumors (>5 cm, 0.8%), the 
percentage of VETC HCC dropped to 8.7%. Recently, 
Villa et al. reported a vascular signature (occurring in 
25% of HCC cases) that was able to predict an unfa-
vorable prognosis and a fast-growing tumor.(9)
The VETC phenotype we studied was consistently 
detectable in the eastern and western series. It was 
also reliably reproducible as shown by the intralabo-
ratory (correlation between TMA and whole section) 
and interlaboratory (correlation among 4 reviewers) 
data consistency. We easily found (and then looked 
for) VETC in tumoral areas where the capillary pat-
tern was largely missing. Notably, the good correla-
tion of VETC occurrence between TMA and whole 
section suggested that this feature could be reliably 
detected in small tissue samples as in core needle 
biopsies. Indeed, one of the main limitations of HCC 
biopsy is the poor performance in the detection of 
microvascular invasion, an adverse prognostic feature 
that was well correlated with the VETC in our series 
(P < 0.001). We also observed VETC to be associated 
with the macrotrabecular pattern of growth as well as 
with the recently reported MTM subtype,(13,14) which 
occurred in 7.8% of our series. Indeed, hematoxylin 
and eosin staining of tumor areas with thick trabecu-
lae revealed a VETC pattern in a significant percent-
age of cases, as opposed to a compact pattern.
Most importantly, we provided a morphological 
tool that is easily incorporable into clinical practice 
with a cutoff value for VETC HCC of 55% (i.e., most 
of the tumor area). This cutoff revealed to be a robust 
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HCCs with a significant impact on OS, DFS, and 
early recurrence. Early recurrent HCCs are those 
showing an intrahepatic/extrahepatic dissemination, 
well in keeping with the endothelial entrapment of 
clusters of malignant hepatocytes, robustly sustained 
by novel vascular connections. Notably, VETC val-
ues were independent from HCC etiology and were 
retained in smaller and earlier tumors (≤5 cm) as well 
as in HCCs already showing micro/macrovascular 
invasion. These data suggest the potential value of 
discerning VETC HCC, to optimize further the indi-
vidual therapeutic approach. Our results validate and 
strongly extend the findings of Fang et al. in a large 
multicentered cohort that includes HCV-related and 
FIg. 2. (A) Morphologic features of a MTM HCC, showing a thick trabecular pattern of growth in more than half of the tumor area. 
(B) Clinical and pathologic features associated with MTM HCC (*P < 0.05, **P < 0.001; χ2 test). (C) Impact of MTM on survival of 
HCC patients.
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HBV-related HCCs, revealing VETC as an indepen-
dent predictor of shorter recurrence-free survival in 
164 HBV-related HCC patients.(11)
Interestingly, VETC also maintained a significant 
prognostic impact in HCCs unrelated to p53 activation, 
detected using surrogate immunohistochemical mark-
ers (GS and β-catenin) that likely picked up a spec-
trum of Wnt/β-catenin deregulated cases. We had 122 
cases (22.6%) of Wnt/β-catenin deregulated HCC, 
and we found that 26.2% (32 of 122) of these showed 
taBle 4. Clinical and pathological Features associated With MtM HCC (n = 541)
n (%) Non-MTM HCC (n [%]) MTM HCC (n [%]) P Value
Clinical Features
Age >60 years 290 (53.6) 272 of 499 (54.5) 18 of 42 (42.9) 0.151
Male sex 423 (78.2) 392 of 499 (78.6) 31 of 42 (73.8) 0.559
Alcohol 30 (5.5) 29 of 499 (5.8) 1 of 42 (2.4) 0.721
HCV infection 188 (34.8) 177 of 499 (35.5) 11 of 42 (26.2) 0.243
HBV infection 280 (51.8) 253 of 499 (50.7) 27 of 42 (64.3) 0.108
BCLC stage B-C* 61 (14.7) 56 of 376 (14.9) 5 of 38 (13.2) 0.819
AFP serum level >400 ng/mL 95 (17.6) 77 of 499 (15.4) 18 of 42 (42.9) <0.001
Pre-operative treatment 20 (3.7) 18 of 499 (3.6) 2 of 42 (4.8) 0.663
General Macroscopic
Tumor size >5 cm 95 (17.6) 90 of 499 (18.0) 5 of 42 (11.9) 0.401
Multiplicity 88 (16.3) 81 of 499 (16.2) 7 of 42 (16.7) 1.000
Macrovascular invasion 31 (5.7) 29 of 499 (5.8) 2 of 42 (4.8) 1.000
General Microscopic
Edmondson grade III-IV 252 (46.6) 222 of 499 (44.5) 30/42 (71.4) 0.001
Microtrabecular pattern 398 (73.6) 375 of 499 (75.2) 23 of 42 (54.8) 0.006
Macrotrabecular pattern 307 (56.7) 265 of 499 (53.1) 42 of 42 (100.0) <0.001
Pseudoglandular pattern 195 (36.0) 187 of 499 (37.5) 8 of 42 (19.0) 0.019
Compact pattern 234 (43.3) 217 of 499 (43.5) 17 of 42 (40.5) 0.748
Microvascular invasion 292 (54.0) 264 of 499 (52.9) 28 of 42 (66.7) 0.107
Capsule infiltration 297 (54.9) 270 of 499 (54.1) 27 of 42 (64.3) 0.258
Inflammatory infiltrates 144 (26.6) 127 of 499 (25.5) 17 of 42 (40.5) 0.045
Cirrhosis 271 (50.1) 250 of 499 (50.1) 21 of 42 (50.0) 1.000
Tumor Cytological Findings
Cholestasis 93 (17.2) 88 of 499 (17.6) 5 of 42 (11.9) 0.403
Clear cells 159 (29.4) 140 of 499 (28.1) 19 of 42 (45.2) 0.022
Pleomorphic cells 156 (28.8) 141 of 499 (28.3) 15 of 42 (35.7) 0.375
Multinucleated cells 148 (27.4) 130 of 499 (26.1) 18 of 42 (42.9) 0.021
Sarcomatous changes 12 (2.2) 11 of 499 (2.2) 1 of 42 (2.4) 1.000
Hyaline bodies 113 (20.9) 101/499 (20.2) 12 of 42 (28.6) 0.234
Tumor Variants
Lymphoepithelioma-like 6 (1.1) 6 of 499 (1.2) 0 of 42 (0.0) 1.000
Sarcomatoid 3 (0.6) 3 of 499 (0.6) 0 of 42 (0.0) 1.000
Scirrhous 8 (1.5) 8 of 499 (1.6) 0 of 42 (0.0) 1.000
Steatohepatitic 38 (7.0) 35 of 499 (7.0) 3 of 42 (7.1) 1.000
VETC Phenotype 102 (18.9) 87 of 499 (17.4) 15 of 42 (35.7) 0.006
Molecular Phenotype†
p53+ 108 (20.0) 90 of 499 (18.0) 18 of 42 (42.9) <0.001
βcatenin/GS+ 122 (22.6) 120 of 499 (24.0) 2 of 42 (4.8) 0.006
Double positive 11 (2.0) 8 of 499 (1.6) 3 of 42 (7.1) 0.046
Double negative 300 (55.5) 281 of 499 (56.3) 19 of 42 (45.2) 0.196
*Available in 414 cases.
†p53+: p53+ and βcatenin/GS-; βcatenin/GS+: p53- and βcatenin/GS+; double positive: p53+ and βcatenin/GS+; and double negative: 
p53- and βcatenin/GS-.
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the VETC phenotype, a greater proportion compared 
with the Wnt/β-catenin-unrelated group (16.7%, 70 of 
419; P = 0.025). Interestingly, VETC was also signifi-
cantly enriched (P  =  0.006) in MTM HCC (35.7%, 
15 of 42) as compared with non-MTM HCC (17.4%, 
87 of 499). VETC enrichment in a subpopulation of 
Wnt/β-catenin deregulated HCCs, which usually have 
a better outcome, as well as in MTM HCC, which 
usually have a poorer prognosis, could seem contra-
dictory. However, in the clinically robust molecular 
HCC classification,(15) the S1 subclass—with an aber-
rant activation of the canonical Wnt/β-catenin path-
way (by transforming growth factor β rather than by 
β-catenin mutations)—was characterized by a greater 
risk of earlier recurrence and more vascular invasion, 
two features in keeping with the profile of our VETC 
HCC. It has been also shown that the Wnt/β-catenin 
pathway contributes to angiogenesis, infiltration, and 
metastasis by regulating the expression of angiogenic 
factors.(16) We are therefore tempted to speculate that 
VETC enrichment might have occurred in an HCC 
subpopulation with Wnt/β-catenin deregulation not 
necessarily related to gene mutations.
Notably, in the present study we also noticed con-
sistent pathologic/molecular correlations with the 
data shown by Calderaro et al. (Supporting Table S5), 
emphasizing the role of gene drivers (or lack of them) 
in modulating HCC morphology and growth.(13) 
Despite being associated with the p53 phenotype, 
high AFP levels, poor differentiation and VETC phe-
notype, the recently reported MTM subtype of HCC 
did not show an independent prognostic value at mul-
tivariable analysis. However, as also suggested by Ziol 
et al., MTM HCC was associated with an unfavorable 
FIg. 3. Clinicopathologic features associated with p53+ HCC (A) and β-catenin/GS+ HCC (B). (*P < 0.05, **P < 0.001; χ2 test).
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outcome (univariable analysis; early recurrence and 
OS) in tumors greater than 5 cm.(14) Overall, this study 
suggests that MTM HCC likely identifies a subset 
of aggressive HCCs of larger size, which was a small 
proportion in our series. Additional useful histopatho-
logical features provided here with negative impact on 
survival were poor tumor differentiation (Edmonson 
III-IV), the exceptionally rare sarcomatoid variant, 
microvascular invasion, and hyaline bodies.(17)
Reliable prognostic parameters of HCC behavior 
are still an unmet need in the clinical practice. In this 
study, we have proven that the VETC phenotype, a 
distinct pattern involving most of the tumor area, is 
found in about one-fifth of resectable HCCs, and 
is significantly associated with OS, DFS, and early 
recurrence. This vascular phenotype can be detected 
with increasing frequency, from the earliest stages 
of HCC, and its assessment is easy and reliably 
reproducible even in small-sized tissues such as liver 
biopsy. In advanced HCC, VETC has been recently 
suggested to act as a predictor of sorafenib benefit(12); 
however, our data support the assessment of the 
VETC phenotype also in nonadvanced and resectable 
HCC for the identification of HCC patients at high 
risk of a more rapid tumor progression. VETC is a 
noncapillary network of HCC vessels that is prone to 
open into larger ones, as to deliver metastatic tumor 
cell clusters.(11)
The results presented here emphasize the role of 
the microenvironment, particularly of endothelial 
cells, in the aggressive behavior of HCC and highlight 
the heterogenous features of HCC angiogenesis. We 
also believe that the characterization of the vascular 
phenotype and the recognition of the vascular hetero-
geneity can be helpful, in the future, for an individual 
anti-angiogenetic treatment of HCC.
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